Claims for Patent: 8,642,753

Summary for Patent: 8,642,753

Title:	Modulation of glucagon receptor expression
Abstract:	Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.
Inventor(s):	Freier; Susan M. (San Diego, CA), Dobie; Kenneth W. (Del Mar, CA), McKay; Robert (Poway, CA), Bhanot; Sanjay (Carlsbad, CA)
Assignee:	Isis Pharmaceuticals, Inc. (Carlsbad, CA)
Application Number:	13/566,642
Patent Claims:	1. An antisense compound 12 to 50 nucleobases in length comprising at least one of a modified internucleoside linkage, a high affinity modified sugar or a modified nucleobase, wherein said antisense compound comprises a nucleobase sequence comprising at least 8 contiguous nucleobases complementary to an equal length portion of an intron of the nucleic acid molecule encoding human glucagon receptor in SEQ ID NO:18, wherein the nucleobase sequence of the antisense compound is at least 90% complementary to SEQ ID NO: 18 over the entire length of the antisense compound. 2. The compound of claim 1 which is 15 to 30 nucleobases in length. 3. The compound of claim 1 which is 20 nucleobases in length. 4. The compound of claim 1 having at least 95% complementarity with SEQ ID NO: 18 as measured over the entire length of the antisense compound. 5. The compound of claim 1 having at least one 2'-O-methoxyethyl sugar moiety. 6. The compound of claim 1 having at least one phosphorothioate internucleoside linkage. 7. The compound of claim 1 having at least one 5-methylcytosine. 8. The compound of claim 1 that is a pharmaceutically acceptable salt. 9. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable diluent or carrier. 10. The compound of claim 1 comprising at least one high affinity modified sugar moiety selected from the group consisting of a 2'-O-(2-methoxyethyl), a 2'-O-methyl or a locked nucleic acid. 11. The compound of claim 1 wherein the compound is chimeric, comprising deoxynucleotides in a gap region, at least one high affinity modified sugar in each of a first wing region, and a second wing region, said wing regions flanking the gap region on the 5' end and the 3' end, respectively, and at least one phosphorothioate modified internucleoside linkage. 12. The compound of claim 11 wherein the high affinity modified sugar is a 2'-O-(2-methoxyethyl. 13. The compound of claim 1 wherein at least a portion of said compound hybridizes with RNA to form an oligonucleotide-RNA duplex. 14. The compound of claim 11 further comprising at least one 5-methylcytosine modified nucleobase. 15. The compound of claim 1 comprising a pharmaceutically acceptable salt. 16. A method of inhibiting the expression of human glucagon receptor in cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1, wherein said antisense compound inhibits the expression of the human glucagon receptor. 17. A method of treating or delaying the onset of a metabolic disease or condition associated with glucagon receptor in a human comprising administering to said human a therapeutically or prophylactically effective amount of the antisense compound of claim 1, wherein said antisense compound inhibits the expression of the human glucagon receptor, thereby treating or delaying the onset of the metabolic disease or condition. 18. The method of claim 17, wherein the metabolic disease or condition is diabetes, obesity, hyperglycemia, primary hyperglucagonemia, insulin deficiency or insulin resistance. 19. The method of claim 18 wherein the diabetes is Type 2 diabetes. 20. The method of claim 17, wherein the metabolic disease or condition is associated with elevated blood glucose levels, elevated blood triglyceride levels or elevated blood cholesterol levels.

Details for Patent 8,642,753

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2023-04-28
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2023-04-28
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2023-04-28